Publications 2018
426.
Rodríguez-Ortiz ME, Pontillo C, Rodríguez M, Zürbig P, Mischak H, Ortiz A.
Novel Urinary Biomarkers For Improved Prediction Of Progressive eGFR Loss In Early Chronic Kidney Disease Stages And In High Risk Individuals Without Chronic Kidney Disease
Sci Rep. 2018, 8(1):15940.
425.
Huang QF, Van Keer J, Zhang ZY, Trenson S, Nkuipou-Kenfack E, Van Aelst LNL, Yang WY, Thijs L, Wei FF, Ciarka A, Vanhaecke J, Janssens S, Van Cleemput J, Mischak H, Staessen JA.
Urinary proteomic signatures associated with β-blockade and heart rate in heart transplant recipients
PLoS One. 2018, 13(9):e0204439.
424.
Wallbach M, Zürbig P, Dihazi H, Müller GA, Wachter R, Beige J, Koziolek MJ, Mischak H.
Kidney protective effects of baroreflex activation therapy in patients with resistant hypertension
J Clin Hypertens (Greenwich). 2018, 20(10):1519-1526.
423.
Latosinska A., Frantzi M., Merseburger AS, Mischak H.
Promise and Implementation of Proteomic Prostate Cancer Biomarkers
Diagnostics (Basel). 2018, 8(3):57.
422.
Markoska K, Pejchinovski M, Pontillo C, Zürbig P, Jacobs L, Smith A, Masin-Spasovska J, Stojceva-Taneva O, Polenakovic M, Magni F, Mischak H, Spasovski G.
Urinary peptide biomarker panel associated with an improvement in estimated glomerular filtration rate in chronic kidney disease patients
Nephrol Dial Transplant. 2018, 33(5):751-759.
421.
Huang QF, Trenson S, Zhang ZY, Van Keer J, Van Aelst LNL, Yang WY, Nkuipou-Kenfack E, Thijs L, Wei FF, Mujaj B, Ciarka A, Droogné W, Vanhaecke J, Janssens S, Van Cleemput J, Mischak H, Staessen JA.
Biomarkers to Assess Right Heart Pressures in Recipients of a Heart Transplant: A Proof-of-Concept Study
Transplant Direct. 2018, 4(5):e346.
420.
Frantzi M, Latosinska A, Kontostathi G, Mischak H.
Clinical Proteomics: Closing the Gap from Discovery to Implementation
Proteomics. 2018, 18(14):e1700463. Epub 2018 Jul 8.
419.
Tofte N, Lindhardt M, Adamova K, Beige J, Beulens JWJ, Birkenfeld AL, Currie G, Delles C, Dimos I, Francová L, Frimodt-Møller M, Girman P, Göke R, Havrdova T, Kooy A, Mischak H, Navis G, Nijpels G, Noutsou M, Ortiz A, Parvanova A, Persson F, Ruggenenti PL, Rutters F, Rychlík I, Spasovski G, Speeckaert M, Trillini M, von der Leyen H, Rossing P.
Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes
Diabet Med. 2018, 35(10):1375-1382. Epub 2018 Jun 6.
418.
Zhang ZY, Nkuipou-Kenfack E, Yang WY, Wei FF, Cauwenberghs N, Thijs L, Huang QF, Feng YM, Schanstra JP, Kuznetsova T, Voigt JU, Verhamme P, Mischak H, Staessen JA.
Epidemiologic observations guiding clinical application of a urinary peptidomic marker of diastolic left ventricular dysfunction
J Am Soc Hypertens. 2018, 12(6):438-447.e4. Epub 2018 Mar 21.
417.
Lygirou V, Latosinska A, Makridakis M, Mullen W, Delles C, Schanstra JP, Zoidakis J, Pieske B, Mischak H, Vlahou A.
Plasma proteomic analysis reveals altered protein abundances in cardiovascular disease
J Transl Med. 2018, 16(1):104.
416.
Currie GE, von Scholten BJ, Mary S, Flores Guerrero JL, Lindhardt M, Reinhard H, Jacobsen PK, Mullen W, Parving HH, Mischak H, Rossing P, Delles C.
Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria
Cardiovasc Diabetol. 2018, 17(1):50.
415.
Liu Y, Pejchinovski M, Wang X, Fu X, Castelletti D, Watnick TJ, Arcaro A, Siwy J, Mullen W, Mischak H, Serra AL.
Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease
Sci Rep. 2018, 8(1):5584.
414.
Magalhães P, Pontillo C, Pejchinovski M, Siwy J, Krochmal M, Makridakis M, Carrick E, Klein J, Mullen W, Jankowski J, Vlahou A, Mischak H, Schanstra JP, Zürbig P, Pape L.
Comparison of Urine and Plasma Peptidome Indicates Selectivity in Renal Peptide Handling
Proteomics Clin Appl. 2018, 12(5):e1700163. Epub 2018 Apr 23.
413.
Zhang ZY, Trenson S, Yang WY, Zoidakis J, Nkuipou-Kenfack E, Van Keer J, Schanstra JP, Van Aelst L, Vanhaecke J, Janssens S, Verhamme P, Van Cleemput J, Mischak H, Vlahou A, Staessen JA.
P879: Myocardial proteomic signatures in end-stage dilated and ischemic cardiomyopathy compared with normal human hearts
European Heart Journal. 2018;39(Suppl 1):ehy564.P879.
412.
Zhang Z-Y, Trenson S, Yang W-Y, Zoidakis J, Nkuipou-Kenfack E, Huang Q-F, Van Keer J, Schanstra JP, Van Aelst L, Thijs L, Vanhaecke J, Janssens S, Verhamme P, Van Cleemput J, Mischak H, Vlahou A, Staessen JA.
A0221: Myocardial proteomic signatures in end-stage dilated and ischemic cardiomyopathy compared with normal human hearts
Journal of Hypertension 2018, 36(Suppl 1):e3.
411.
Siwy J, Mischak H, Klein T, von Eynatten M.
FO041: Urinary proteomics may unmask the renal potential of the DPP-4 inhibitor linagliptin in patients with diabetic kidney disease
Nephrology Dialysis and Transplantation 2018, 33(Suppl 1):i35–i36.
410.
Siwy J, Magalhães P, Schepers E, Pontillo C, Vlahou A, Glorieux G, Mischak H.
Value of urinary proteome-based classifier associated with chronic kidney disease and its progression in the prognosis of a patient-relevant endpoint, mortality
Nephrology Dialysis Transplantation 2018, 33(Suppl 1):i100–i101.
409.
Siwy J, Mischak H, Klein T, von Eynatten M.
Urin-Proteomanalyse als möglicher Indikator für das Behandlungspotential des DPP-4-Inhibitors Linagliptin bei Patienten mit diabetischer Nierenerkrankung
Diabetologie und Stoffwechsel 2018, 13(S 01):S67.
408.
Siwy J, Mischak H, Klein T, von Eynatten M.
Urinary proteomics may unmask the renal potential of the dipeptidyl peptidase (DPP)-4 inhibitor linagliptin in patients with diabetic kidney disease (DKD)
Diabetologia 2018, 61(Suppl 1):S383.
407.
Ricci P, Magalhães P, Krochmal M, Pejchinovski M, Daina E, Caruso MR, Remuzzi G, Umbhauer M, Pape L, Mischak H, Decramer S, Schaefer F, Schanstra JP, Cereghini S, Zürbig P.
FP050: Urinary peptidome analysis allows non-invasive diagnosis of the RCAD syndrome
Nephrology Dialysis Transplantation 2018, 33(Suppl 1):i64.
406.
Currie G, von Scholten BJ, Lindhardt M, Mary S, Mischak H, Rossing P, Delles C.
Differential regulation of urinary peptides between men and women at early stages of diabetic nephropathy
Endocrine Abstracts 2018, 59:P084.
405.
Stroggilos R, Makridakis M, Latosinska A, Fragkoulis C, Mullen W, Mischak H, Ntoumas K, Drekolias D, Zoidakis J, Vlahou A.
O-1 – Defining the proteomic subtypes of non-muscle invasive bladder cancer
European Urology Supplements 2018, 17(10):e2475.
404.
Reddy P, Pontillo C, Jankowski J, Mischak H.
Peptidomics of Body Fluids
Integration of Omics Approaches and Systems Biology for Clinical Applications. Wiley
2018, Chapter 7, pp. 113–128.
403.
Magalhães P, Drube J, Schaefer F, Mischak H, Klein J, Schanstra J, Pape L, Zürbig P.
FP754 – A urinary proteome-based classifier for the diagnosis of chronic kidney disease in children
Nephrology Dialysis and Transplantation
2018, 33(Suppl. 1):i300–i301.
402.
Berry M, Galinier M, Delmas C, Fournier P, Desmoulin F, Turkieh A, Mischak H, Mullen W, Barutaut M, Eurlings L, Brunner La Rocca HP, Butler J, Roncalli J, Evaristi MF, Cohen-Solal A, Escamilla R, Ferrieres J, Koukoui F, Smih F, Rouet P.
Discovery and validation of a new biomarker for heart failure diagnostic
Archives of Cardiovascular Diseases Supplements 2018, 10(2):203.
401.
Krochmal M, Schanstra JP, Mischak H.
Urinary peptidomics in kidney disease and drug research
Expert Opin Drug Discov. 2018, 13(3):259-268.
400.
Currie G, von Scholten BJ, Lindhardt M, Rejnard H, Jacobsen P, Mullen W, Parving HH, Mischak H, Rossing P, Delles C.
Sex-specific regulation of urinary peptides in early diabetic nephropathy
Journal of Hypertension 2018, 36(Suppl 1):e240.
399.
Latosinska A, Frantzi M, Vlahou A, Merseburger AS, Mischak H.
Clinical Proteomics for Precision Medicine: The Bladder Cancer Case
Proteomics Clin Appl. 2018, 12(2). Epub 2017 Oct 25.
398.
Dacheva I, Reich M, Nobl M, Ceglowska K, Wasiak J, Siwy J, Zürbig P, Mischak H, Koch FH, Kopitz J, Kretz FT, Tandogan T, Auffarth GU, Koss MJ.
[Proteome analysis of undiluted vitreous humor in patients with branch retinal vein occlusion]
Ophthalmologe. 2018, 115(3):203-215.
397.
Belczacka I, Latosinska A, Siwy J, Metzger J, Merseburger AS, Mischak H, Vlahou A, Frantzi M, Jankowski V.
Urinary CE-MS peptide marker pattern for detection of solid tumors
Sci Rep. 2018, 8(1):5227.
396.
Lindhardt M, Persson F, Oxlund C, Jacobsen IA, Zürbig P, Mischak H, Rossing P, Heerspink HJ.
Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension
Nephrol Dial Transplant. 2018, 33(2):296-303.
395.
Marx D, Metzger J, Pejchinovski M, Gil RB, Frantzi M, Latosinska A, Belczacka I, Heinzmann SS, Husi H, Zoidakis J, Klingele M, Herget-Rosenthal S.
Proteomics and Metabolomics for AKI Diagnosis
Semin Nephrol. 2018, 38(1):63-87.
394.
Pejchinovski M, Siwy J, Mullen W, Mischak H, Petri MA, Burkly LC, Wei R.
Urine peptidomic biomarkers for diagnosis of patients with systematic lupus erythematosus
Lupus. 2018, 27(1):6-16. Epub 2017 May 5.
393.
Latosinska A, Hulko M, Speidel R, Mischak H, Storr M, Krause B.
Removal of Cell-Activating Substances Using Dialyzers With Various Permeability Profiles
Artif Organs. 2018, 42(1):78-87. Epub 2017 Jul 26.